McNicoll, Lewis & Vlak Reiterates Affymax Buy, $12 PT

McNicoll, Lewis & Vlak reiterated its Affymax AFFY Buy rating and $12 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, "AFFY ended 2Q:11 with $73.6M in cash and equivalents, and $39.7M in short term investments. Based on the 2011 operating expense guidance of $105-$110M, the company has approximately one year of cash available. Yesterday, AFFY filed a mixed shelf offering of $100M, although we believe it has adequate cash through approval." Shares of Affymax closed today at $4.37, up 8.17% from Wednesday's market close.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorReiterationAnalyst RatingsBiotechnologyHealth CareLewis & VlakMcNicoll
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!